BioWorld

Sep. 10, 2004

SGX, Roche Partner To Use FAST To Discover Antivirals

Entering the first major pharmaceutical deal for its Fragments of Active Structures drug discovery technology, Structural GenomiX formed an alliance with F. Hoffmann-La Roche Ltd. to discover new antiviral therapeutics. (BioWorld Today) Read More

InKine, FDA Agree On SPA For INKP-102 Phase III Trial

Transcytosis Research Lending Hope In Long Fight Against HIV

Push For Public Posting Of Clinical Trial Data Continues

Graffinity Closes Merger With MyoContract, Forms Santhera

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...